State of Wisconsin Investment Board
GALT icon

State of Wisconsin Investment Board’s Galectin Therapeutics GALT Stock Holding History

State of Wisconsin Investment Board’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-60,700
Closed -$174K – 1709
2019
Q4 		$174K Buy
60,700
+9,126
+18% +$31.7K ﹤0.01% 1590
2019
Q3 		$189K Buy
+51,574
New +$186K ﹤0.01% 1507

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State of Wisconsin Investment Board's GALT Position: Q1 2020 in Review

State of Wisconsin Investment Board sold out of Galectin Therapeutics (GALT) in Q1 2020, closing a stake of 60,700 shares — an estimated $174K sold.

State of Wisconsin Investment Board first reported a position in GALT in Q3 2019 and held it in 2 quarters. The position peaked at $189K in Q3 2019. 77 funds tracked by Wall St. Rank hold GALT as of Q1 2020.

  • State of Wisconsin Investment Board reported no remaining Galectin Therapeutics position as of Q1 2020 after selling out during the quarter.
  • State of Wisconsin Investment Board sold 60,700 Galectin Therapeutics shares in Q1 2020, an estimated $174K.
  • State of Wisconsin Investment Board first reported a position in Galectin Therapeutics in Q3 2019 and held it in 2 quarters.
  • State of Wisconsin Investment Board's Galectin Therapeutics position peaked at $189K in Q3 2019.
  • 77 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2020.

Based on State of Wisconsin Investment Board's 13F filing for Q1 2020, filed 6 May 2020.